Plain-English translation of NCT06245356 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new chemotherapy option called trifluridine/tipiracil combined with other cancer drugs for people with advanced colorectal or gastroesophageal cancer who have a rare genetic condition called DPD deficiency. DPD deficiency makes it dangerous to use some standard chemotherapy drugs, so researchers want to see if this medication is a safer alternative that still helps control cancer growth and improves survival.
People with DPD deficiency cannot safely receive common chemotherapy drugs like 5-fluorouracil or capecitabine because their bodies cannot break down these drugs properly, which can cause severe side effects. This trial exists to find out whether this new medication is a safe and effective option for treating advanced cancer in this group of patients.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication (trifluridine/tipiracil) along with and one additional drug chosen based on your cancer type (either , , , or ) every 2 weeks. You would have CT scans every 2 months to check how your cancer is responding, complete quality-of-life questionnaires, and optionally provide blood samples for genetic and drug-metabolism research. The trial will monitor your safety and how well the treatment works until your cancer progresses or the study ends.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
France